利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

704 条记录 (耗时 0.053 秒)

    Heat shock protein 90 inhibitor dosing methods
    111.
    发明申请
    Heat shock protein 90 inhibitor dosing methods 审中-公开
    热休克蛋白90抑制剂给药方法

    公开(公告)号：US20100022635A1

    公开(公告)日：2010-01-28

    申请号：US12462012

    申请日：2009-07-28

    申请人： Roger A. Rajewski

    发明人： Roger A. Rajewski

    IPC分类号： A61K31/352 ,  A61P35/00 ,  A61P3/10

    CPC分类号： A61K31/352 ,  A61K31/00 ,  Y02A50/414

    摘要： The disclosure provides novel dosing regimens for Hsp90 inhibitors for use in the treatment or prevention of a neurodegenerative disorder, an autoimmune disorder, or cancer. The methods involve administering one or more doses of a therapeutically effective amount of at least one Hsp90 inhibitor to a subject in need thereof such that no more than a single dose is administered within a period of about 7 days.

    摘要翻译： 本公开提供了用于治疗或预防神经变性疾病，自身免疫性疾病或癌症的Hsp90抑制剂的新型给药方案。 所述方法包括向有需要的受试者施用一个或多个剂量的治疗有效量的至少一种Hsp90抑制剂，使得在约7天的时间内施用不超过一个剂量。

    Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
    112.
    发明授权
    Sulfoalkyl ether-alkyl ether cyclodextrin derivatives 有权
    磺烷基醚 - 烷基醚环糊精衍生物

    公开(公告)号：US07625878B2

    公开(公告)日：2009-12-01

    申请号：US11413597

    申请日：2006-04-28

    申请人： Valentino J. Stella ,  Serena Tongiani

    发明人： Valentino J. Stella ,  Serena Tongiani

    IPC分类号： A61K31/724

    CPC分类号： C08B37/0015 ,  A61K31/724 ,  A61K47/6951 ,  B82Y5/00 ,  C08B37/0012

    摘要： A sulfoalkyl ether-alkyl ether cyclodextrin (SAE-AE-CD) derivative is provided. The SAE-AE-CD possesses advantages over known SAE-CD and AE-CD derivatives as well as over the parent cyclodextrin by being more water soluble and less membrane disturbing. The SAE-AE-CD includes at least one sulfoalkyl ether group and at least one alkyl ether group even though the degree of substitution for the functional groups can be different. The SAE functional group can be present in molar excess over the AE functional group and vice versa. The total degree of substitution of the cyclodextrin, with respect to both functional groups, can be varied such that a minority or a majority of the hydroxyl moieties of the CD are derivatized. The SAE-AE-CD derivative can be used to solubilize compounds with insufficient water solubility. In some cases, they also stabilize compounds in solution against degradation or to solubilize degradation products formed during degradation. In addition, SAE-AE-CD can also be used for other purposes such as osmotic agents, agents used to mask the taste of problematic drugs. Surprisingly, while AE-CDs are known to be toxic by being membrane disturbing, SAE-AE-CDs are less membrane disturbing and therefore have greater safety.

    摘要翻译： 提供磺基烷基醚 - 烷基醚环糊精（SAE-AE-CD）衍生物。 SAE-AE-CD具有比已知的SAE-CD和AE-CD衍生物以及通过更多的水溶性和更少的膜干扰的母体环糊精的优点。 尽管官能团的取代度可以不同，SAE-AE-CD还包括至少一个磺基烷基醚基团和至少一个烷基醚基团。 SAE官能团的摩尔量可以超过AE官能团，反之亦然。 相对于两个官能团，环糊精的总取代度可以变化，使得CD的少数或大部分羟基部分被衍生化。 SAE-AE-CD衍生物可用于溶解水溶性不足的化合物。 在某些情况下，它们也稳定溶液中的化合物以防止降解或溶解降解过程中形成的降解产物。 此外，SAE-AE-CD也可以用于其他目的，例如渗透剂，用于掩盖有问题的药物的味道的试剂。 令人惊讶的是，虽然AE-CD通过膜阻塞而具有毒性，但是SAE-AE-CD较少的膜扰动，因此具有更高的安全性。

    SOURCE AFFINE RECONSTRUCTION FOR MEDICAL IMAGING
    113.
    发明申请
    SOURCE AFFINE RECONSTRUCTION FOR MEDICAL IMAGING 有权
    用于医学成像的资源重建

    公开(公告)号：US20090182220A1

    公开(公告)日：2009-07-16

    申请号：US12335434

    申请日：2008-12-15

    申请人： Shannon D. Blunt ,  Mihai Popescu ,  Tsz Ping Chan

    发明人： Shannon D. Blunt ,  Mihai Popescu ,  Tsz Ping Chan

    IPC分类号： A61B5/05 ,  A61B5/0476

    CPC分类号： G06T11/006

    摘要： Performing medical imaging. The generation of medical images, which includes a Source AFFine Image REconstruction (SAFFIRE) algorithm, is based on an iterative implementation of minimum mean-square error (MMSE) estimation within an affine-transformed solution space and utilizes a matched filter bank initialization coupled with energy normalization of each successive estimate. An incoherent integration technique provides an alternative implementation strategy to either increase signal-to-noise ratio (SNR) or generalize the estimator to accommodate temporally-separated interference sources. In addition, the estimator solution may be employed to determine volumetric constraints with which to re-apply the estimator to further improve the estimation accuracy.

    摘要翻译： 进行医学影像 包含源AFFine Image REconstruction（SAFFIRE）算法的医学图像的生成基于仿射变换解空间内的最小均方误差（MMSE）估计的迭代实现，并利用匹配的滤波器组初始化与 每次连续估计的能量归一化。 非相干积分技术提供了替代实施策略，以增加信噪比（SNR）或推广估计器以适应时间上分离的干扰源。 另外，可以使用估计器解决方案来确定用于重新应用估计器的体积约束，以进一步提高估计精度。

    Process and apparatus for size selective separation of micro- and nano-particles
    119.
    发明授权
    Process and apparatus for size selective separation of micro- and nano-particles 有权
    用于微粒和纳米颗粒尺寸选择性分离的方法和装置

    公开(公告)号：US6113795A

    公开(公告)日：2000-09-05

    申请号：US193660

    申请日：1998-11-17

    申请人： Bala Subramaniam ,  Roger A. Rajewski ,  David J. Bochniak

    发明人： Bala Subramaniam ,  Roger A. Rajewski ,  David J. Bochniak

    IPC分类号： B01D11/04 ,  B01D61/14 ,  C30B7/00 ,  B01D61/00

    CPC分类号： B01D11/0407 ,  B01D61/14 ,  C30B29/605 ,  C30B7/00

    摘要： Processes and apparatuses are provided for continuously harvesting particles from organic solution-laden near-critical and supercritical fluids. Broadly, the processes and apparatuses utilize a filter or separator comprising a thin membrane supported on a sintered stainless steel tube. A feed stream comprising the desired particles, a supercritical antisolvent for the particles (preferably CO.sub.2), and a solvent for the particles, is contacted with the membrane layer of the filter under supercritical conditions for the mixture of antisolvent and solvent. The preferred antisolvents are substantially miscible with the solvent and have a critical temperature of less than 160.degree. C. The desired particles are retained by the filter while the solvent and most of the antisolvent pass through the filter, resulting in separation of the particles from the solvent.

    摘要翻译： 提供了从有机溶液附近临界和超临界流体中连续收集颗粒的方法和装置。 广泛地，该方法和设备利用一种过滤器或分离器，其包括负载在烧结的不锈钢管上的薄膜。 包含所需颗粒的进料流，用于颗粒的超临界反溶剂（优选CO 2）和颗粒的溶剂在超临界条件下与反应溶剂和溶剂的混合物与过滤器的膜层接触。 优选的反溶剂与溶剂基本上是可混溶的并且具有小于160℃的临界温度。所需的颗粒被过滤器保留，而溶剂和大部分反溶剂通过过滤器，导致颗粒从 溶剂。

    Isolated domains of type IV collagen to modify cell and tissue interactions
    120.
    发明授权
    Isolated domains of type IV collagen to modify cell and tissue interactions 失效
    IV型胶原的分离结构域，以修饰细胞和组织相互作用

    公开(公告)号：US5856184A

    公开(公告)日：1999-01-05

    申请号：US800965

    申请日：1997-02-18

    申请人： Michael P. Sarras, Jr. ,  Billy G. Hudson

    发明人： Michael P. Sarras, Jr. ,  Billy G. Hudson

    IPC分类号： A61K38/39 ,  A61M5/32 ,  A61P43/00 ,  C07K16/18 ,  C12N5/00 ,  C12N5/08

    CPC分类号： C12N5/0018 ,  A61K38/39 ,  C07K16/18 ,  A61K2039/505 ,  C12N2501/998 ,  Y10S514/801

    摘要： The instant invention demonstrates that the 7S domain of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation affects cell division, cell differentiation, and morphogenesis.

    摘要翻译： 本发明证明IV型胶原的7S结构域破坏细胞聚集和组织发育。 mesoglea的结构变化，细胞增殖的抑制和细胞分化模式的变化伴随着细胞聚集体的阻断，这表明阻塞可能是由于mesoglea（细胞外基质）结构的改变以及伴随细胞行为的影响。 IV型胶原蛋白在初始形成mesoglea中具有关键作用，并且mesoglea形成的扰动影响细胞分裂，细胞分化和形态发生。